SCHEMBL10169167

SCHEMBL10169167

Cc1ccc(C(N)=O)c(Nc2ccc(N3CCN(C)CC3)cc2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 6/20 0.56
STAT6 P42226 1/20 0.52
BRD4 O60885 2/20 0.52
EML4 Q9HC35 4/20 0.52
ALK Q9UM73 4/20 0.52
RET P07949 3/20 0.52
ROS1 P08922 3/20 0.52
FLT3 P36888 3/20 0.52
CCNA2 P20248 1/20 0.50
CDK2 P24941 1/20 0.50
CCNA1 P78396 1/20 0.50
SLC2A1 P11166 1/20 0.49
BTK Q06187 1/20 0.48
KCNH2 Q12809 1/20 0.48
CSF1R P07333 1/20 0.48
CDK4 P11802 3/20 0.48
CCND1 P24385 3/20 0.48
CCNT1 O60563 2/20 0.48
CDK9 P50750 2/20 0.48
CDK6 Q00534 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL894714 0.87 SYK (0.55) SYKSTAT6BRD4EML4ALK
SCHEMBL10169158 0.84 BTK (0.53) SYKBRD4CCNA2CDK2BTK
SCHEMBL10169338 0.82 SYK (0.52) SYKSTAT6BRD4EML4ALK
SCHEMBL5686083 0.81 NPC1 (0.63) SYKSTAT6BRD4ALKCCNA2
SCHEMBL894971 0.79 SYK (0.52) SYKSTAT6BRD4EML4ALK
SCHEMBL18617242 0.79 SYK (0.53) SYKSTAT6ALKFLT3CCNA2
SCHEMBL14456079 0.77 MAPT (0.54) SYK
SCHEMBL3771350 0.77 MAPT (0.54) SYK
SCHEMBL894903 0.77 BTK (0.49) SYKSTAT6BRD4EML4ALK
SCHEMBL893537 0.77 SYK (0.52) SYKSTAT6BRD4EML4ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586751-B2 Nicotinamide compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-19 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT SYK 22/4885STAT6 438/4885BRD4 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.